Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
December 11, 2023 08:30 ET
|
Coherus BioSciences, Inc.
– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with...
Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma
September 07, 2017 08:10 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent Developments
March 13, 2017 16:05 ET
|
Peregrine Pharmaceuticals Inc.
-- Avid Revenue Guidance Increased to $60 - $65 Million for Full FY 2017 and Contracted Backlog of Future Business Currently at $70 Million ---- Multiple Preclinical Studies Demonstrating...
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2017 and Recent Developments
December 12, 2016 16:05 ET
|
Peregrine Pharmaceuticals Inc.
-- Avid Posts Record Revenue of $23.4 Million During Second Quarter FY 2017 with Contracted Backlog of Future Business Currently at $73 Million -- -- Beta-2 Glycoprotein-1 (β2GP1) Identified as a...
National Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals’ Bavituximab in Multiple Cancers
September 06, 2016 08:45 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers
January 11, 2016 08:05 ET
|
Peregrine Pharmaceuticals Inc.
-- Phase II Study in NSCLC in Collaboration with AstraZeneca Evaluating Bavituximab Plus Durvalumab to Expand Lung Cancer Program in Q1 2016 -- -- Phase II/III Study in HER2-Negative Metastatic...
Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
January 06, 2016 08:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
NCCN Holds Second Annual State Oncology Society Forum
March 21, 2013 15:09 ET
|
National Comprehensive Cancer Network
FORT WASHINGTON, Pa., March 21, 2013 (GLOBE NEWSWIRE) -- The National Comprehensive Cancer Network® (NCCN®) held its second annual State Oncology Society Forum during the NCCN 18th Annual...
NCCN Roundtable Considers the Changing Oncology Landscape: Evolution or Revolution?
March 21, 2013 10:30 ET
|
National Comprehensive Cancer Network
FORT WASHINGTON, Pa., March 21, 2013 (GLOBE NEWSWIRE) -- The National Comprehensive Cancer Network® (NCCN®) hosted its second roundtable of the NCCN 18th Annual Conference: Advancing the...
NCCN Adds Two New Member Institutions
March 19, 2013 10:51 ET
|
National Comprehensive Cancer Network
FORT WASHINGTON, Pa., March 19, 2013 (GLOBE NEWSWIRE) -- The National Comprehensive Cancer Network® (NCCN®), an alliance of the world's leading cancer centers dedicated to improving the...